Get the Stockscreener App
31.82
0.32%
0.10
Overview
News
Price History
Option Chain
Financials
Why SLP Down?
Discussions
Forecast
Stock Split
Dividend History
Simulations Plus Inc stock is traded at $31.82, with a volume of 253.80K.
It is up +0.32% in the last 24 hours and up +3.72% over the past month.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
See More
Previous Close:
$31.72
Open:
$31.99
24h Volume:
253.80K
Relative Volume:
1.36
Market Cap:
$638.14M
Revenue:
$66.98M
Net Income/Loss:
$9.65M
P/E Ratio:
63.64
EPS:
0.5
Net Cash Flow:
$10.19M
1W Performance:
+15.37%
1M Performance:
+3.72%
6M Performance:
-36.14%
1Y Performance:
-19.22%
1-Day Range:
$31.62
$32.57
1-Week Range:
$27.76
$33.76
52-Week Range:
$27.07
$51.22
Simulations Plus Inc Stock (SLP) Company Profile
Name
Simulations Plus Inc
Sector
Industry
Phone
661-723-7723
Address
42505 10TH STREET WEST, LANCASTER, CA
Compare SLP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLP
Simulations Plus Inc
|
31.82 | 638.14M | 66.98M | 9.65M | 10.19M | 0.50 |
|
VEEV
Veeva Systems Inc
|
226.76 | 36.93B | 2.57B | 615.26M | 996.76M | 3.32 |
|
SOLV
Solventum Corp
|
72.48 | 12.43B | 8.26B | 66.00M | 1.17B | 0.00 |
|
TEM
Tempus Ai Inc
|
62.98 | 10.01B | 640.44M | -743.28M | -206.93M | 0.00 |
|
DOCS
Doximity Inc
|
53.39 | 9.94B | 493.63M | 160.55M | 162.20M | 0.55 |
|
HQY
Healthequity Inc
|
102.47 | 8.91B | 1.10B | 105.67M | -197.98M | 0.1475 |
Simulations Plus Inc Stock (SLP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Initiated | Stephens | Overweight |
| Jul-29-24 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-16-24 | Initiated | JMP Securities | Mkt Perform |
| Jun-28-24 | Initiated | William Blair | Outperform |
| May-09-23 | Initiated | BTIG Research | Buy |
| Oct-26-21 | Upgrade | Craig Hallum | Hold → Buy |
| Jan-12-21 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-16-20 | Initiated | Raymond James | Outperform |
| Sep-08-20 | Initiated | Oppenheimer | Outperform |
| Jan-06-20 | Initiated | Craig Hallum | Buy |
View All
Simulations Plus Inc Stock (SLP) Latest News
Wall Street Analysts Predict a 56.99% Upside in Simulations Plus (SLP): Here's What You Should Know - Yahoo Finance
JMP Securities Initiates Coverage of Simulations Plus (SLP) with Market Perform Recommendation - MSN
Simulations Plus (NASDAQ:SLP) Stock Price Up 7.8%Here's Why - MarketBeat
Principal Financial Group Inc. Buys 2,226 Shares of Simulations Plus, Inc. (NASDAQ:SLP) - Defense World
Detailed Analysis of Molecular Modeling for Drug Development - openPR
Uncovering the Future: Pharmaceutical Simulation Software - openPR
Simulations Plus (SLP) Stock Jumps 8.9%: Will It Continue to Soar? - Yahoo Finance
Simulations Plus stock hits 52-week low at $27.2 amid market shifts - Investing.com Canada
Simulations Plus stock hits 52-week low at $27.2 amid market shifts By Investing.com - Investing.com South Africa
How Much Upside is Left in Simulations Plus (SLP)? Wall Street Analysts Think 77.52% - MSN
Simulations Plus to Participate in the BTIG Digital Health Forum - BioSpace
Biosimulation Market Dynamics and Future Opportunities | 2024 - openPR
Simulations Plus, Inc. (NASDAQ:SLP) Given Consensus Rating of “Buy” by Brokerages - Defense World
Royce & Associates LP Acquires 53,092 Shares of Simulations Plus, Inc. (NASDAQ:SLP) - MarketBeat
Simulations Plus, Inc. (NASDAQ:SLP) Receives $51.40 Average PT from Brokerages - MarketBeat
Simulations Plus (NASDAQ:SLP) Upgraded at Stephens - MarketBeat
Simulations Plus, Inc. (NASDAQ:SLP) Shares Bought by US Bancorp DE - Defense World
Simulations Plus (NASDAQ:SLP) Now Covered by Analysts at Stephens - MarketBeat
Where are the Opportunities in (SLP) - Stock Traders Daily
Simulations Plus Inc (SLP) Shares Gap Down to $30.515 on Nov 14 - GuruFocus.com
Simulations Plus Wins FDA Grant for Revolutionary Drug Delivery Modeling Technology | SLP Stock News - StockTitan
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables - Business Wire
Biosimulation Market on Track for Strong Growth by 2031 | Certara, Simulations Plus Inc, Rhenovia Pharma - openPR
William Blair Issues Positive Forecast for SLP Earnings - Defense World
William Blair Boosts Earnings Estimates for Simulations Plus - MarketBeat
We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be Conservative - Simply Wall St
Q1 EPS Forecast for Simulations Plus Raised by Analyst - MarketBeat
We Think Simulations Plus' (NASDAQ:SLP) Solid Earnings Are Understated - Yahoo Finance
Simulations Plus to Participate in the Stephens Annual Investment Conference - Business Wire
Simulations Plus (NASDAQ:SLP) Given "Outperform" Rating at William Blair - MarketBeat
StockNews.com Downgrades Simulations Plus (NASDAQ:SLP) to Sell - Defense World
Insider Sale: Director and 10% Owner Walter Woltosz Sells 20,000 Shares of Simulations Plus Inc (SLP) - GuruFocus.com
Simulations Plus, Inc. (NASDAQ:SLP) Director Sells $553,200.00 in Stock - MarketBeat
Simulations Plus director Walter Woltosz sells $553,200 in stock - Investing.com
Simulations Plus director Walter Woltosz sells $553,200 in stock By Investing.com - Investing.com UK
Simulations Plus (NASDAQ:SLP) Stock Rating Lowered by StockNews.com - MarketBeat
Conestoga Capital Advisors LLC Trims Stock Position in Simulations Plus, Inc. (NASDAQ:SLP) - MarketBeat
Simulations Plus Halts Dividends to Boost Long-Term Growth: What It Means for Investors - Nasdaq
Simulations Plus secures FDA grant for drug testing tech By Investing.com - Investing.com Canada
Simulations Plus (NASDAQ:SLP) Sets New 12-Month LowTime to Sell? - MarketBeat
Simulations Plus stock hits 52-week low at $29.32 amid market shifts - Investing.com
Simulations Plus secures FDA grant for drug testing tech - Investing.com
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations - The Bakersfield Californian
Biosimulation Market is expected to Double Its Size by Upcoming - openPR
Tributary Capital Management LLC Buys 115,122 Shares of Simulations Plus, Inc. (NASDAQ:SLP) - MarketBeat
Q2 Earnings Forecast for SLP Issued By William Blair - Defense World
Brokers Offer Predictions for SLP Q2 Earnings - MarketBeat
Simulations Plus, Inc. (NASDAQ:SLP) Receives $56.00 Consensus Price Target from Analysts - Defense World
Simulations Plus' Q4 Earnings Top Estimates on Solid Revenue Growth - MSN
Simulations Plus (NASDAQ:SLP) Posts Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Simulations Plus Inc Stock (SLP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Simulations Plus Inc Stock (SLP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WOLTOSZ WALTER S | Director |
Oct 01 '24 |
Sale |
31.26 |
20,000 |
625,200 |
3,481,592 |
| WEINER DANIEL L | Director |
Sep 27 '24 |
Sale |
31.54 |
750 |
23,655 |
6,994 |
0.88%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):